Ticker

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and institutional collaborations Continued progress toward IND-enabling activities for DNase I program Ended the year with $7.9 million of cash to fund operations FRAMINGHAM, MA / ACCESS Newswire / March 13, 2026 / Xenetic…

Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Ainos (NASDAQ: AIMD - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Profitability This table compares Xenetic Biosciences and Ainos'

Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 55,692 shares, a growth of 245.0% from the January 29th total of 16,141 shares. Based on an average daily volume of 28,113 shares, the short-interest ratio

Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Valuation and Earnings This table compares Cumberland

Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends. Profitability This table compares Crinetics Pharmaceuticals and Xenetic